COMMUNIQUÉS West-GlobeNewswire

Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
28/01/2026
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and [...]
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
28/01/2026
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional [...]
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
28/01/2026
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic [...]
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
28/01/2026
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, [...]
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
28/01/2026
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT regimen continues under [...]
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
28/01/2026
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
28/01/2026
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026 Vireo plans to appoint Chris Hagedorn to its Board of Directors MINNEAPOLIS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vireo [...]
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
28/01/2026
Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss Jupiter, Florida, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” [...]
DXS International plc (AQSE: DXSP): Half-year Financial Report
28/01/2026
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results [...]
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
28/01/2026
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab has the [...]
OKYO Pharma Announces Successful Type C Meeting with the FDA
28/01/2026
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage [...]
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
28/01/2026
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
OMass Therapeutics Appoints Jonathan Montagu as Chair of the Board of Directors
28/01/2026
OXFORD, United Kingdom, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins [...]
Newly published research further validates GlucoModicum’s path to high-precision, non-invasive glucose monitor
28/01/2026
The study explains the mechanism behind up to 100× sensitivity amplification in glucose sensors The article was published in Biosensors and Bioelectronics , the leading peer-reviewed journal in the field GlucoModicum [...]
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
28/01/2026
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental [...]
Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
28/01/2026
Ad hoc announcement pursuant to Art. 53 LR Regulatory dossier to obtain marketing authorization for QUVIVIQ has been submitted to ANVISA in Brazil Allschwil, Switzerland – January 28, 2026 Idorsia Ltd (SIX: IDIA) [...]
HepatoBurn Investigated (SAFETY REPORT) Is This Liver Formula Legit? Side Effects, Risks, and Warnings Explained
28/01/2026
Las Vegas, Nevada, Jan. 28, 2026 (GLOBE NEWSWIRE) -- If you are researching HepatoBurn reviews in 2026 , you are not alone. Interest in this supplement has surged quietly, not because of viral ads or influencer hype, [...]
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
28/01/2026
GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has [...]
Profound Medical Announces Upcoming Investor Events
27/01/2026
TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, [...]

Pages